Related Experiment Videos
Two-dimensional echocardiography using a subcostal approach in patients with COPD
Chest
|November 1, 1985
Summary
Two-dimensional echocardiography (2-DE) from a subcostal window offers reliable parameters for assessing pulmonary artery hypertension (PAH) in chronic obstructive pulmonary disease (COPD) patients. This method quantifies right heart changes, aiding PAH assessment.
Area of Science:
- Cardiology
- Pulmonology
- Medical Imaging
Background:
- Pulmonary artery hypertension (PAH) is a serious complication in patients with chronic obstructive pulmonary disease (COPD).
- Accurate assessment of PAH in COPD is crucial for management and prognosis.
- Non-invasive imaging techniques are valuable for evaluating cardiac involvement in respiratory diseases.
Purpose of the Study:
- To evaluate the efficacy of two-dimensional echocardiography (2-DE) utilizing a subcostal window for assessing pulmonary artery hypertension (PAH) in patients with chronic obstructive pulmonary disease (COPD).
- To determine if specific 2-DE derived parameters can reliably quantify the morphologic changes in the right heart associated with PAH in COPD.
Main Methods:
- A case-control study comparing 15 COPD patients with PAH to 15 healthy controls.
- Two-dimensional echocardiography (2-DE) performed using a subcostal approach.
- Measurements included tricuspid annulus (TA) dimensions, right ventricle (RV) short axis, and right ventricular anterior wall (AW) thickness, normalized to body surface area (2D-index).
Main Results:
- The 2D-index (TA X RV + AW/body surface area) was significantly higher in COPD patients with PAH (871.2 +/- 314.5 mm/m2) compared to controls (378.3 +/- 47.6 mm/m2).
- The 2D-index demonstrated a strong correlation with mean pulmonary artery pressure (MPAP) (r=0.9055, p<0.001).
Conclusions:
- 2-DE parameters derived from the subcostal window can effectively quantify right heart morphologic alterations in COPD patients with PAH.
- These echocardiographic parameters are valuable tools for the non-invasive assessment of pulmonary artery hypertension in the context of COPD.